Eli Lilly agreed to acquire CrossBridge Bio for up to $300 million, aiming to expand its oncology pipeline with dual-payload antibody-drug conjugates designed to deliver two cytotoxic payloads to tumor cells. Lilly expects the deal to close in the second quarter of 2026, and CrossBridge said its lead asset CBB-120 is on track for an IND submission to the FDA later this year. The acquisition reflects continuing investor and pharma attention toward ADC differentiation beyond conventional single-payload approaches, particularly as companies look for ways to widen the therapeutic index and potentially address resistance. CrossBridge’s platform is framed as targeting TROP2 with a dual-payload strategy. Lilly’s move also adds another acquisition-driven platform expansion to its cancer strategy, coming alongside other ADC and oncology investments highlighted in coverage around the deal announcement.